Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 4/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL190036 | 1.00 | LMNA (0.48) | LMNAMAPK1KEAP1NFE2L2CYP2D6 | |
| SCHEMBL14691171 | 1.00 | LMNA (0.48) | LMNAMAPK1KEAP1NFE2L2CYP2D6 | |
| SCHEMBL571797 | 1.00 | LMNA (0.48) | LMNAMAPK1KEAP1NFE2L2CYP2D6 | |
| SCHEMBL28707494 | 0.85 | LMNA (0.52) | LMNAMAPK1KEAP1NFE2L2CYP2D6 | |
| SCHEMBL12180786 | 0.85 | LMNA (0.49) | LMNAMAPK1KEAP1NFE2L2CYP2D6 | |
| SCHEMBL27486731 | 0.85 | LMNA (0.49) | LMNAMAPK1KEAP1NFE2L2CYP2D6 | |
| SCHEMBL7139715 | 0.85 | SRC (0.47) | LMNAMAPK1KEAP1NFE2L2CYP2D6 | |
| SCHEMBL8070685 | 0.85 | SRC (0.47) | LMNAMAPK1KEAP1NFE2L2CYP2D6 | |
| SCHEMBL8108955 | 0.83 | LMNA (0.67) | LMNAHPGDTP53HDAC1 | |
| SCHEMBL530337 | 0.83 | LMNA (0.67) | LMNAHPGDTP53HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 667 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110195910-A1 | USE OF TOCOTRIENOL COMPOSITION FOR THE PREVENTION OF CANCER | DAVOS LIFE SCIENCE PTE. LTD. (SG) | 2011-08-11 | — | — | US | claimed |
| EP-2337561-A1 | USE OF TOCOTRIENOL COMPOSITION FOR THE PREVENTION OF CANCER | Davos Life Science Pte. Ltd. (SG) | 2011-06-29 | — | — | EP | claimed |
| US-7864129-B2 | Radio frequency medical treatment device and system and usage method thereof | NAMIKI SEIMITSU HOUSEKI KABUSHIKI KAISHA (JP) | 2011-01-04 | — | — | US | claimed |
| WO-2010047663-A1 | USE OF TOCOTRIENOL COMPOSITION FOR THE PREVENTION OF CANCER | DAVOS LIFE SCIENCE PTE. LTD. (SG) | 2010-04-29 | — | — | WO | claimed |
| US-12637492-B2 | Peptide inhibitors of focal adhesion kinase activity and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260034066-A1 | NOVEL PHARMACEUTICAL COMPOSITION | NOVARTIS AG (CH) | 2026-02-05 | — | — | US | disclosed |
| US-12521386-B2 | Small molecule inhibitors of the androgen receptor activity and/or expression and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2026-01-13 | — | — | US | disclosed |
| US-20260000729-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | UNIV MICHIGAN REGENTS (US) | 2026-01-01 | — | — | US | disclosed |
| US-12509468-B2 | Quindoline compounds and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250326771-A1 | PIPERAZINE DERIVATIVES USEFUL IN HIV THERAPY | VIIV HEALTHCARE CO (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250276953-A1 | SMALL MOLECULE SIRTUIN INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2025-09-04 | — | — | US | disclosed |
| US-20250189527-A1 | COMPOSITIONS AND METHODS FOR DETECTING, PREDICTING RISK OF DEVELOPING, AND TREATING LEPTOMENINGEAL DISEASE | DUKE UNIVERSITY | 2025-06-12 | — | — | US | disclosed |
| WO-2005046516-A2 | MEDICAL IMPLANTS AND ANTI-SCARRING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2005-05-26 | — | — | WO | disclosed |
| WO-2005020794-A2 | TAXANE CHEMOSENSITIVITY PREDICTION TEST | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005018683-A2 | ANASTOMOTIC CONNECTOR DEVICES | ANGIOTECH INTERNATIONAL AG (CH) | 2005-03-03 | — | — | WO | disclosed |
| US-20040260318-A1 | Anastomotic connector devices | ANGIOTECH INTERNATIONAL AG (CH) | 2004-12-23 | — | — | US | disclosed |
| WO-2004064734-A2 | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | THRESHOLD PHARMACEUTICALS, INC. (US) | 2004-08-05 | — | — | WO | disclosed |
| US-20040048923-A1 | Therapeutic compounds | VIVESTO AB (SE) | 2004-03-11 | — | — | US | disclosed |
| WO-2004009538-A1 | RETINOL DERIVATIVES, THEIR USE IN THE TREATMENT OF CANCER AND FOR POTENTIATING THE EFFICACY OF OTHER CYTOTOXIC AGENTS | ARDENIA INVESTMENTS LTD. (GB) | 2004-01-29 | — | — | WO | disclosed |
| EP-1287854-A1 | Anti-cancer combinations of DMXAA and paclitaxel or docetaxel | Cancer Research Ventures Limited (GB) | 2003-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260000729-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | CXCR4, CXCL12, CXCR6 | LMNA 2767/4885MAPK1 1777/4885KEAP1 1561/4885 |
| US-20250326771-A1 | PIPERAZINE DERIVATIVES USEFUL IN HIV THERAPY | CCR5, THPO, IL5 | LMNA 4100/4885MAPK1 2914/4885KEAP1 3192/4885 |
| US-20040048923-A1 | Therapeutic compounds | TTPA, SLC7A11, SLC6A6 | LMNA 3364/4885MAPK1 2612/4885KEAP1 396/4885 |
| US-12509468-B2 | Quindoline compounds and uses thereof | TPD52L2, BRDT, RECQL | LMNA 2504/4885MAPK1 3757/4885KEAP1 1665/4885 |
| US-20110195910-A1 | USE OF TOCOTRIENOL COMPOSITION FOR THE PREVENTION OF CANCER | TTPA, DHCR7, CYP24A1 | LMNA 1809/4885MAPK1 4065/4885KEAP1 89/4885 |
| US-20260034066-A1 | NOVEL PHARMACEUTICAL COMPOSITION | TAF1L, TAF1, TAF5 | LMNA 4489/4885MAPK1 1392/4885KEAP1 4859/4885 |
| US-20250276953-A1 | SMALL MOLECULE SIRTUIN INHIBITORS AND USES THEREOF | SIRT6, SIRT2, SIRT1 | LMNA 2635/4885MAPK1 4218/4885KEAP1 248/4885 |
| US-12637492-B2 | Peptide inhibitors of focal adhesion kinase activity and uses thereof | PTK2, ILK, FPR2 | LMNA 1096/4885MAPK1 765/4885KEAP1 2760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.